GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
NMPA
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances
The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...
China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends
The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...
Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment
Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...
NMPA Releases 78th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 78th batch of reference drugs for...
China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision
The National Medical Products Administration (NMPA) has issued the “Rules for the Application of Administrative...
Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits
The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...
China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...
GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September
The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...
NMPA Launches Pilot Program to Streamline Supplementary Drug Approval Process
The National Medical Products Administration (NMPA) has unveiled the “Pilot Work Plan for Optimizing the...
CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases
The Center for Drug Evaluation (CDE) has released its annual drug review report for 2023,...
NMPA Proposes Streamlined Market Approval Process for Domestically Produced Overseas Drugs
The National Medical Products Administration (NMPA) has released a draft proposal titled “Optimizing the Market...
NMPA Expands Generic Drug Catalog with 74th and 75th Batches for Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 74th and 75th batches of reference...
Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements
Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...
Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel
The Shanghai medical products administration has released the “Measures for the Management of Key Quality...
China’s NMPA Issues Guidelines for Inspection of Third-Party Online Drug Trading Platforms
The National Medical Products Administration (NMPA) has issued a new set of “Guidelines for the...
China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...